Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon, a global healthcare company, for an enterprise valuation of $11.75 billion.
According to a BSE filing, the deal values Organon at $14.00 per share in an all-cash transaction. This acquisition is expected to strengthen Sun Pharma’s presence in the women’s health and biosimilars market.
The combined company will have a global footprint, with a presence in over 150 countries and a revenue of $12.4 billion.
Sun Pharma will become a top-10 global player in the biosimilars market and a leading player in the established brands and branded generics business. The acquisition will also enhance Sun Pharma’s innovative medicines portfolio.
The acquisition of Organon is aligned with Sun Pharma’s strategy of growing its innovative medicines business.
Organon’s portfolio, global footprint, and strong stakeholder relationships will complement Sun Pharma’s existing strengths and enhance long-term value creation. The deal is expected to be completed after receiving regulatory approvals.
As part of the agreement, Organon’s stockholders will receive $14.00 per share in cash. The acquisition will be funded through a combination of debt and internal cash reserves.
Sun Pharma’s management believes that the acquisition will create significant value for its shareholders and stakeholders.
The acquisition reinforces Sun Pharma’s position as a leading player in the global pharmaceutical industry. With a strong portfolio of products and a global presence, Sun Pharma is well-positioned to drive growth and innovation in the healthcare sector.
Disclaimer: The information provided is for educational purposes only and does not constitute financial advice. We are not registered financial advisors. Please conduct your own research and consult a qualified advisor before making investment decisions. Any investment decisions you make based on this information are solely at your own risk.
